Table 1.
Baseline clinicopathologic features of patients with melanoma.
| Characteristics | NAIVE (n = 5) | IO PROG (n = 5) |
|---|---|---|
| Agea, median (range) | 60 (25–78) | 46 (31–77) |
| Sex, n (%) | ||
| Male | 4 (80) | 4 (80) |
| Female | 1 (20) | 1 (20) |
| Prior treatment, n (%) | ||
| None | 5 (100) | |
| PD-1 inhibitor | 1 (20) | |
| PD-1+CTLA-4 inhibitor | 4 (80) | |
| Mutation, n (%) | ||
| BRAF V600E | 5 (100) | 5 (100) |
| LDH, n (%) | ||
| Normal | 3 (60) | 4 (80) |
| Elevated | 2 (40) | 1 (20) |
| Site, n (%) | ||
| Lymph node | 3 (60) | 4 (80) |
| Bowel | 1 (20) | 1 (20) |
| Subcutaneous chest | 1 (20) | |
| Stage at diagnosis, n (%) | ||
| Stage I | 3 (60) | |
| Stage II | 2 (40) | 1 (20) |
| Stage III | 3 (60) | |
| Stage IV | 1 (20) |
a
Age at time of biopsy shown.